drugset / Trial / NCT00931021

Smoking Cessation Treatment for Head and Neck Cancer Patients

NCT00931021

Phase 0 Terminated 7 enrolled Yale University
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a pilot research study examining the use of varenicline (Chantix) and the nicotine patch. The study is designed to find out whether one of these medications is more effective for smoking cessation with head and neck cancer patients. The study has three parts: 1) two intake sessions; 2) an 8-week treatment phase, and 3) a 3-month follow-up.

Timeline

Start
2009-07
Primary completion
2012-12
Completion
2012-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Nicotine Unknown 21 mg
Comparator Varenicline Small molecule 2 mg

Indications

No indication recorded.